Logo
x

Search

Subscribe Now
AstraZeneca’s Tagrisso (Osimertinib) Secures the EC’s Approval to Treat Unresectable EGFR-Mutated Lung Cancer

AstraZeneca’s Tagrisso (Osimertinib) Secures the EC’s Approval to Treat Unresectable EGFR-Mutated Lung Cancer

  • December 23, 2024
Astellas and Sangamo Therapeutics Partner for Administering Genomic Therapies Targeting Neurological Disorders

Astellas and Sangamo Therapeutics Partner for Administering Genomic Therapies Targeting Neurological Disorders

  • December 23, 2024
Mainz Biomed Partners with Quest Diagnostics to Commercialize its Colorectal Cancer Screening Test

Mainz Biomed Partners with Quest Diagnostics to Commercialize its Colorectal Cancer Screening Test

  • December 23, 2024
Pfizer’s Braftovi (Encorafenib) Secures the US FDA’s Accelerated Approval as a 1L Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

Pfizer’s Braftovi (Encorafenib) Secures the US FDA’s Accelerated Approval as a 1L Treatment of BRAF V600E-Mutant Metastatic Colore...

  • December 23, 2024
Eli Lilly Reports the US FDA’s Approval of Zepbound (Tirzepatide) to Treat Moderate-to-Severe Obstructive Sleep Apnea in Obese Adults

Eli Lilly Reports the US FDA’s Approval of Zepbound (Tirzepatide) to Treat Moderate-to-Severe Obstructive Sleep Apnea in Obese Adu...

  • December 23, 2024
Merck Reports Topline Data from P-III Studies of Doravirine/Islatravir (DOR/ISL) Regimen to Treat Virologically Suppressed HIV-1 Infection

Merck Reports Topline Data from P-III Studies of Doravirine/Islatravir (DOR/ISL) Regimen to Treat Virologically Suppressed HIV-1 I...

  • December 23, 2024
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.